Praxis Capital acquires management rights of health supplement firm SeungMyeong PE firm purchases shares worth $49 mil
Translated by Kim So-in 공개 2021-09-17 12:57:40
이 기사는 2021년 09월 17일 08:08 thebell 에 표출된 기사입니다.
Seoul-based private equity (PE) firm Praxis Capital has acquired South Korean health supplement company SeungMyeong to capitalize on the fast-growing health supplement market and the company’s competitiveness in the global market.Praxis Capital signed a contract with the company to purchase shares worth 58 billion won ($49 million) to secure management rights in July, industry sources said on Wednesday. The acquisition was fully financed through the PE firm’s blind-pool fund.
Established in 2008, SeungMyeong operates health supplement brands like Naturalize and The REAL, whose main product categories include omega 3, propolis, and gamma-linolenic acid.
The company has built overseas networks in North America, Oceania, and Europe over the past 10 years to focus on the product development. It also owns more than 400 stock keeping units and is developing private brands for more than 30 retailers.
Praxis Capital has primarily reviewed the company’s competitiveness in the health supplement market to make the latest investment. The health supplement market was estimated to be worth around 6 trillion won in 2020 and is expected to grow fast in the coming years as consumption trends change. SeungMyeong posted revenue of around 30 billion won in 2020, with an average annual revenue growth of 50% over the last three years.
Praxis Capital plans to further enhance the company’s products beyond the health supplement category through the latest buyout investment as the company’s mainstay products have already secured top positions on the country's major ecommerce platforms such as Naver and Coupang. (Reporting by Ha-na Suh)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- '본업 선방' hy, 자회사 적자폭 축소
- '3년 연속 성장' 본푸드서비스, 그룹 캐시카우 안착
- [IB 풍향계]리벨리온 상장주관사에 시선집중…삼성증권 참전
- [LG CNS IPO]몸값 '7조'...내년초 상장 '최적 스케줄' 무게
- [Korean Paper]외평채 발행 일정 지연, 한국물 발행사는 '고심중'
- [thebell note]국내 ESG채권의 미래
- [방산기업 국산화율 톺아보기]'한국형 구축함·잠수함 산증인' 한화오션
- [뉴 포스코 승부수]10년 전 배운 그대로, 새 실세도 뜬다
- [미래 기다리는 SK이노베이션]IRA '비중국산 분리막' 수혜 기다리는 SKIET
- 목표달성형 성과…라이프운용-KB증권 '대동단결'